Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Ibuprofen/Caffeine FDC vs Ibuprofen in Healthy Volunteers
NCT02629354Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in pain comparing Ibuprofen and Caffeine with Ibuprofen (2 arms). Primary endpoints: Maximum Observed Plasma Concentration of S-ibuprofen, Maximum Observed Plasma Concentration of R-ibuprofen and 4 more. Started Nov 2015; status: completed.
02
Drugs
ibuprofencaffeine
03
Conditions
pain
Beyond the preview
Go deeper on NCT02629354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02629354.